Business
Bioretec Ltd´s business review Q1 2025: Strong net sales in the first quarter; CE approval with comprehensive indications received in January accelerates the future expansion of RemeOs products
This announcement summarizes Bioretec Ltd's business review for January-March 2025. The complete business review is attached to this release as a PDF file and available on the company's website at https://investors.bioretec.com/en/reports_and_presentations
About this update from Bioretec Ltd.
[{"type":"text","content":"Bioretec Ltd Company announcement 15 May 2025 at 8:00 a.m.","length":69,"tagName":"p"},{"type":"text","content":"TAMPERE, Finland, May 15, 2025 /PRNewswire/ -- This announcement summarizes Bioretec Ltd's business review for January-March 2025. The complete business review is attached to this release as a PDF file and available on the company's website at https://investors.bioretec.com/en/reports_and_presentations","length":316,"tagName":"p"},{"type":"text","content":"January - March 2025 in brief","length":29,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In January, Bioretec's RemeOs™ trauma screw product family received comprehensive CE approval, allowing market launch in Europe and non-European countries that recognize the CE mark.","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Commercialization efforts progressed with several new distribution agreements signed in the U.S.","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"The new CE-marked RemeOs products are being transferred into production, and preparations are continuing to increase the manufacturing capacity and ramp up their production.","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Net sales amounted to EUR 1,396 thousand (1-3/2024: EUR 682 thousand). The increase was achieved due to strong sales to China. Scheduling Activa orders for the first quarter allows more resources to be dedicated to RemeOs for the remainder of the year.","length":252,"tagName":"p"}]},{"val":[{"type":"text","content":"The sales margin (excl. other income) was EUR 822 (418) thousand, or 58.9% (61.3%) of net sales. The sales margin was slightly lower due to the increased share of sales to China in the first quarter, where the volume-based procurement policies continued to impact the pricing. Furthermore, the sales margin in the comparison period was suppressed by the planned production shutdown related to the ramp-up of new production capacity.","length":432,"tagName":"p"}]},{"val":[{"type":"text","content":"EBITDA was EUR -1,236 (-1,112) thousand. EBITDA was burdened by increased personnel costs due to headcount growth and additional fixed costs relating to commercialization and R&D projects.","length":192,"tagName":"p"}]},{"val":[{"type":"text","content":"The result for the reporting per...